In Treatment of Bacterial infections Moxipil CL Syrup is a medicine given to children for the treatment of a wide range of bacterial infections. Moxipil CL Syrup also treats bacterial pneumonia, which is a very common condition in children. This medicine inhibits the bacteria from multiplying, thereby arresting their growth. It is also given as an empirical therapy in conditions where the infection-causing bacteria is unknown and as a preventive (prophylactic) antibiotic therapy. It may be given alone or along with some other medicines. Your child may start to feel better within 2 to 3 days of regular dosing. For best results, finish the full course of the medicine without stopping abruptly as doing so may lead to ineffective treatment and worsen your child’s condition. In Treatment of Resistant Tuberculosis (TB) In multidrug-resistant (MDR) tuberculosis, the causative bacteria produce an enzyme called beta-lactamase. This enzyme breaks down the antibiotics and makes them ineffective. As a result, the bacteria become resistant to the antibiotic being used for treatment. Moxipil CL Syrup comprises two active ingredients, Amoxycillin and clavulanic acid. While clavulanic acid stops the enzyme from rendering Amoxycillin ineffective, Amoxycillin works towards killing the tuberculosis-causing bacteria. This makes the combination of Amoxycillin and clavulanic acid an effective treatment for resistant tuberculosis.
Moxipil CL Syrup should be used with caution in patients with kidney disease. Dose adjustment of Moxipil CL Syrup may be needed. Please consult your doctor.
Moxipil CL Syrup should be used with caution in patients with liver disease. Dose adjustment of Moxipil CL Syrup may be needed. Please consult your doctor.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More
Marketer/Manufacturer: Nippon Seiyaku Pvt Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Parenteral Drugs India Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Toubib Pharma Private Limited || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Vrevive Medicure Pvt. Ltd. || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Macleods Pharmaceuticals Pvt Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Aggrowin Pharma || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Alkem Laboratories Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Zennar Life Sciences || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Lancer Health Care Pvt Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Lancer Health Care Pvt Ltd || ₹14.5/tablet (25% cheaper)